A possible increased risk of metamizole-associated neutropenia among COVID-19 patients

Tsahi T. Lerman, Moshe Sagi, Yair Shafir, Liron Sheena, Eytan Cohen, Elad Goldberg, Ilan Krause

Research output: Contribution to journalArticlepeer-review

Abstract

Metamizole is commonly used as analgesic and antipyretic drug. The use of metamizole is prohibited in several countries due to its rare side effect of neutropenia and even agranulocytosis. Among the many symptoms of COVID-19, fever and diffuse pain predominant and therefore it can be assumed that metamizole may be widely used in the current epidemic period. So far, there have been no reports on the safety of metamizole in COVID-19 patients. We describe a series of 3 patients who developed severe neutropenia under metamizole treatment, raising a concern of a possible increased risk of this side effect among COVID-19 patients.

Original languageEnglish
Pages (from-to)2902-2906
Number of pages5
JournalBritish Journal of Clinical Pharmacology
Volume87
Issue number7
DOIs
StatePublished - Jul 2021

Keywords

  • COVID-19
  • SARS-CoV-2
  • adverse drug reaction
  • agranulocytosis
  • dipyrone
  • metamizole
  • neutropenia

Fingerprint

Dive into the research topics of 'A possible increased risk of metamizole-associated neutropenia among COVID-19 patients'. Together they form a unique fingerprint.

Cite this